India Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

India Drug Delivery Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The India Drug Delivery Devices Market is poised at a CAGR of nearly 5.5% during the forecast period (2022-2027).

COVID-19 has significantly impacted the Indian drug delivery devices market during the pandemic due to the shortage of drug delivery devices. For Instance, in September 2022, Bharat Biotech has conducted the product development related to pre-clinical safety evaluation, the large-scale manufacturing scale-up, the formulation, the delivery-device development, and human clinical trials and concluded that the intranasal vaccine will make it easier to deploy in mass immunisation campaigns with an easy-to-administer formulation and delivery device. Such developments are expected to rise in adoption of drug delivery devices in the administration of market growth, driving the market growth in India.

India has the second-largest population in the world according to OECD data. With the increasing population, the demand for better healthcare facilities has also increased. Newer and more efficient ways of drug delivery devices have been positively affected by this demand and hence this market is flourishing in India.

The factors driving the market growth in India include, rising prevalence of chronic diseases, rising technological advancements, innovative strategies adopted by the key market players, among others. It is not just the growing population, but also the increasing prevalence of chronic diseases that have caused a burden on the Indian population. According to International Diabetes Federation report published in 2021, the estimatated number of diabetes patients in 2021 in thousands were 74,194.7 and the number is expected to reach 92,973.7 by 2030. This has proven to be the major factor for the ease in demand for drug delivery devices for the delivery of insulin. Other factors like technological advancements in the field of drug delivery and demand for controlled release drugs have also affected this market positively.

According to the study titled 'Prevalence and Potential Determinants of Chronic Disease Among Elderly in India: Rural-Urban Perspectives' published in March 2022, in India, about 21% of the elderly population reportedly have at least one chronic disease. 17%elderly in rural areas and 29% in urban areas suffer from a chronic disease. Hypertension and diabetes account for about 68% of all chronic diseases.

In addition, in August 2021, Berry Global Group is planning to construct second manufacturing plant and a worldwide centre of excellence for healthcare in Bangalore, India. According to plans released by Berry, it wants to concentrate on its current position in inhalation devices, including models with digital capabilities and the next generation of injectable devices. Such initiatives will lead to increase manufacturing of drug delivery devices, thereby expected to rise in adoption, driving the market growth.

However, an increase in the risk of infections and side effects from these devices and stringent regulatory guidelines for the approval of drug delivery devices have been restraining the growth of this market.

Key Market TrendsBy Route of Administration, Topical Drug Delivery Devices is Estimated to Witness a Healthy Growth in Future.

Topical drug delivery devices are estimated to witness healthy growth in the future attributed to several benefits associated with this type of route of administration such as ease of use, painless, noninvasive delivery, convenience, and superior spreadability. Moreover, segment growth also increases with the increasing prevalence of skin diseases and enhanced patient compliance.

For instance, according to the study titled 'Burden of Disease, Unmet Needs in the Diagnosis and Management of Atopic Dermatitis: An Indian Expert Consensus' published in November 2021, the prevalence of Atopic Dermatitis in India among 6–7-years old is 2.7% and among 13–14 years old is 3.6%. Furthermore, according to the study titled 'Clinical Descriptive Study of Psoriasis in India: Triggers, Morbidities and Coincidences' published in June 2021, 88.74% reported the course of the psoriasis disease as progressive. The prevalence and progressiveness of the skin disease will therefore be expected to increase the adoption of topical drug delivery systems, bolstering this segment's growth.

In addition, with the advent of novel drug delivery systems, topical drug delivery systems have gained pace, in recent times. topical drug delivery systems have been enhanced by the development of advanced time-controlled drug delivery systems, with the help of modern mathematical models, sophisticated instrumentation, and computational power, to revolutionize the entire formulation process. Thus these types of delivery systems are widely adopted in India.

Moreover, according to the study titled ''Recent advancements in transdermal patches: Literature review" published in April 2022, the new and dependable transdermal route of medication administration allows for prolonged drug delivery, and the number of transdermal devices entering the market is anticipated to rise significantly as more research is conducted in this area and researchers' interest in this method of medication delivery grows. Such studies shows the importance of topical drug delivery devices, thereby expected to drive this segment growth further.

Hence, the aforementioned factors are expected to propel the segment's overall growth over the forecast period.

Competitive Landscape

The market studied in India is moderately competitive and comprises international as well as local players. India has been attracting global pharmaceutical players. These companies have benefitted themselves from the Indian market due to increasing demands. This only persuaded many other global companies to enter the Indian market. Many domestic pharmaceutical manufacturers have also established themselves as key players. Some of the major players in the market include, Drägerwerk AG & Co. KGaA, B. Braun SE, Koninklijke Philips N.V., Medtronic Plc, Sanofi, GlaxoSmithKline, among others

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.